Regeneron jumps 11% to a two-year high on Dupixent strength
FROM THE WIRE · FINANCE.YAHOO.COM
Regeneron stock jumped to a two-year high Friday after its Sanofi-partnered inflammation giant, Dupixent, handily beat expectations. Continue Reading
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishA sharp rally in a major biotech driven by a key drug can influence the sector.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Regeneron stock jumped to a two-year high on Friday.
- 02Dupixent, partnered with Sanofi, handily beat expectations.
- 03The stock rose 11% in the session.
NEWS IMPACT AND MARKET REACTIONChange from the reference price
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets